| HOME >> BIOLOGY >> TECHNOLOGY |
Dr. Tarr made a statement saying, "The clinical potential of this work cannot be overstated. Historically, successful vaccines against viruses have required the production of antibodies, and this is likely to be the case for Hepatitis C virus. Identifying regions of the virus that are able to induce broadly reactive neutralizing antibodies is a significant milestone in the development of a HCV vaccine, which will have distinct healthcare benefits for hepatitis sufferers, and could also help us design vaccines for other chronic viral diseases such as HIV."
"We are also currently exploring the possibility of improving liver transplantation success rates by passively infusing people with these antibodies," said Dr. Tarr, "Additionally we are using the information gained by identifying and characterizing the antibody responses to Hepatitis C virus to design new ways of making vaccine candidates. If the antibodies we have discovered can be reproduced by vaccination, control of the disease might be possible."
The Hepatitis C virus affects over 180 million people worldwide. Infection with the virus can lead to liver cancer, and is the most common reason for liver transplantation in the United States and the United Kingdom.
About The British Midlands Development Corporation
The British Midlands Development Corporation is the North American economic development agency for central England. The Midlands region is located just one hour north of London and includes the major commercial centers of Birmingham, Nottingham, Coventry and Northampton.
As an agency funded by the UK Government, The British Midlands
Development Corporation provides specialist advice and support to North
American companies seeking to establish a presence or expand a current
operation in the region. The British Midlands Development Corporation
provides access to business networks, details about sources for grants and
funding, business support services,
'/>"/>
| SOURCE The British Midlands Development Corporation Copyright©2007 PR Newswire. All rights reserved |